PATENT CLAIM ANALYSIS

Application Number: 16068558
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "291000"]

Abstract:
The present invention provides tacrolimus for use in the treatment in a human subject of a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementias (FTDs), wherein the tacrolimus is for administration at a therapeutically-effective dose which does not cause immunosuppression in the subject.

Claim (Index 23):
The method of  claim 7 , wherein the tacrolimus is administered at a daily dose of at least 0.001 mg/kg, 0.002 mg/kg, 0.003 mg/kg, 0.004 mg/kg, 0.005 mg/kg, 0.006 mg/kg, 0.007 mg/kg, 0.008 mg/kg, 0.009 mg/kg, 0.010 mg/kg, 0.011 mg/kg, 0.012 mg/kg, 0.013 mg/kg, 0.014 mg/kg, 0.015 mg/kg, 0.016 mg/kg, 0.017 mg/kg, 0.018 mg/kg, or 0.019 mg/kg.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 95.0
- Lexical Diversity: 1.29268
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15370032', '14742164', '14398379', '14935024', '14354404']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7615997689984259
- 35 USC 102 Novelty (BERT): 0.515636193435306
- Combined Prediction Score: 0.7370034114421139
- Mean Citation Score: 236.962136
- Max Citation Score: 248.97473
- Similarity Product: 145.10690262459516

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test